Home / Market News / $CRBP
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

RBC Capital Markets Adjusts Price Target on Corbus Pharmaceuticals

Nov 11, 2026, 2:20 PM UTC · Primary ticker $CRBP

RBC Capital Markets has lowered its price target for Corbus Pharmaceuticals from $36 to $33, while maintaining an Outperform rating. This adjustment reflects the firm's updated outlook following Corbus's recent Q3 financial results and clinical updates, suggesting a re-evaluation of the company's near-term prospects.

RBC Capital Markets has reduced its price target for Corbus Pharmaceuticals (CRBP) from $36 to $33. This decision comes after the company's third-quarter financial reporting and clinical updates, indicating that RBC has likely adjusted its valuation model based on new information. While the Outperform rating is maintained, the lower price target suggests a more conservative outlook on the stock's potential upside in the short to medium term. For traders, this could signal a slight negative sentiment, potentially leading to some downward pressure on the stock, although the maintained Outperform rating might temper significant declines. The speculative risk designation remains, highlighting the inherent volatility and uncertainty associated with biotechnology companies.

$CRBP negative price target cut
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.